Analyst Price Target is $7.67
▲ +338.10% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SCYNEXIS in the last 3 months. The average price target is $7.67, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 338.10% upside from the last price of $1.75.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in SCYNEXIS. This Buy consensus rating has held steady for over two years.
SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.